Purevax RCCh

Lapsed

This medicine's authorisation has lapsed

vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections

Overview

The marketing authorisation for Purevax RCCh has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Purevax RCCh : EPAR - Summary for the public

Product information

Purevax RCCh : EPAR - Product Information

Purevax RCCh : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Purevax RCCh
• Active substance:
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
  • attenuated Chlamydophila felis (905 strain)
• International non-proprietary name (INN) or common name:
  vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
• Species:
  Cats
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI06AH

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged 8 weeks and older:

• against feline viral rhinotracheitis to reduce clinical signs;
• against calicivirus infection to reduce clinical signs and excretion;
• against Chlamydophila felis infection to reduce clinical signs.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.

The duration of immunity is 1 year after the last (re-)vaccination.

Authorisation details

• EMA product number:
  EMEA/V/C/000092
• Marketing authorisation holder:
  Merial

  29 Avenue Tony Garnier; 69007 Lyon; France

• Marketing authorisation issued:
  22/02/2005
• Lapse of marketing authorisation:
  22/02/2008
• Revision:
  8

Assessment history

Changes since initial authorisation of medicine

Purevax RCCh : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Purevax RCCh : EPAR - Scientific Discussion

Purevax RCCh : EPAR - Procedural steps taken before authorisation